SIRT1, a novel transcriptional downstream target of CD44, linking its deacetylase activity to tumor cell invasion/metastasis

Our tetracycline-off-inducible CD44 expression system previously established in mouse model, revealed that activation of CD44 with its major ligand hyaluronan (HA) promoted breast cancer (BC) metastasis to the liver. To identify the mechanisms that underpin CD44-promoted BC cell invasion, microarray...

Full description

Saved in:
Bibliographic Details
Published inFrontiers in oncology Vol. 12; p. 1038121
Main Authors Ahmad, Salma M S, Al-Mansoob, Maryam, Ouhtit, Allal
Format Journal Article
LanguageEnglish
Published Switzerland Frontiers Media S.A 23.11.2022
Subjects
breast cancer
CD44
hyaluronan
metastasis
Oncology
SIRT1
breast cancer
metastasis
SIRT1
hyaluronan
CD44
Online AccessGet full text

Cover

More Information
Summary:Our tetracycline-off-inducible CD44 expression system previously established in mouse model, revealed that activation of CD44 with its major ligand hyaluronan (HA) promoted breast cancer (BC) metastasis to the liver. To identify the mechanisms that underpin CD44-promoted BC cell invasion, microarray gene expression profiling using RNA samples from (Tet)-Off-regulated expression system of CD44s in MCF7 cells, revealed a set of upregulated genes including, nuclear sirtuin-1 ( also known as NAD-dependent deacetylase), an enzyme that requires NAD as a cofactor to deacetylate several histones and transcription factors. It stimulates various oncogenic pathways promoting tumorigenesis. This data suggests that is a potential novel transcriptional target of CD44-downstream signaling that promote BC cell invasion/metastasis. This review will discuss the evidence supporting this hypothesis as well as the mechanisms linking to cell proliferation and invasion.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
Reviewed by: Honghao Yu, Huazhong University of Science and Technology, China
Edited by: Vasiliki Gkretsi, European University Cyprus, Cyprus
This article was submitted to Molecular and Cellular Oncology, a section of the journal Frontiers in Oncology
ISSN:2234-943X
2234-943X
DOI:10.3389/fonc.2022.1038121